Facebook
X
LinkedIn
ForwardCord Blood Red Cell Concentrates for Preterm Neonate Transfusion: Insights From the Multicenter BORN Trial
The BORN trial found that transfusing extremely preterm newborns with red blood cells from cord blood (CB-RBCs), rather than from adult donors, reduced severe retinopathy of prematurity and bronchopulmonary dysplasia. Moving this into routine practice depends on cord blood banks reliably producing and stocking these units. This CME activity is based on a study in Transfusion that looked at how nine Italian cord blood banks produced and managed CB-RBC units during the trial:
- Supply: of 451 units processed, 107 were transfused to 69 babies. For 67 transfusion requests, no compatible unit was available.
- Quality: all centers met European quality standards, and centers that processed more units hit their hematocrit target more often.
- Bottlenecks: waiting for bacterial testing results and the need for gamma irradiation were the main limits on availability.
The activity covers whether CB-RBC production can be repeated reliably across centers, how inventory can be improved, for example by extending storage to 21 days, and what it takes to set up a CB-RBC inventory.
Target Audience
Healthcare Professionals
Learning Objectives
- Describe why transfusing extremely preterm newborns with cord blood red blood cells (CB-RBCs) is clinically useful, including the BORN trial’s findings on retinopathy of prematurity and bronchopulmonary dysplasia.
- Assess whether CB-RBC units can be produced reliably across multiple cord blood banks and still meet European quality standards.
- Identify the operational barriers that limit CB-RBC availability, including thresholds on how much cord blood is collected, delays waiting for bacterial testing results, and the need for gamma irradiation.
- Discuss ways to make CB-RBC stock more useful, such as storing units for longer, to support use in clinical practice.
Activity Disclosure
No commercial support has been accepted related to the development or publication of this activity.
This activity underwent peer review in line with the standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.
Course summary
- 1.00 AMA PRA Category 1 Credit(s)™
Article Authors
Pellegrino C, Papacci P, Dani C, Cresi F, Remaschi G, Ansaldi G, Giannantonio C, Campagnoli MF, Vania B, Fabbri M, Penta de Vera d’Aragona R, Molisso A, Beccastrini E, Dragonetti A, Pasciuto T, Gabbrellini S, Baroni S, Serrao F, Purcaro V, Raffaeli G, Villa S, Prati D, Mondello I, Falcone A, Patti ML, Boggini T, Bergamaschi P, Mozzetta I, Valentini CG, Locatelli E, Albiani R, Besso FG, Cantone GV, Coscia A, Trimarchi A, Capone A, Ghiradello S, Vento G, and Teofili L.
CME Editor
Julie Katz Karp MD
Julie Katz Karp MD has nothing to disclose.
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 1 hour. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, up to 3 attempts and a score of 70% or better is needed to pass the post test and claim CC credit. [ACGME competency/CC category: Medical Knowledge].
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™